Tirdzniecība Altimmune, Inc. - ALT CFD
Pievienot izlasei- Kopsavilkums
- Vēsturiskie Dati
- Notikumi
- Peļņas Atskaite
- Bilance
- Naudas Plūsma
- Īpašums
Tirdzniecības Nosacījumi
| Starpība | 0.07 | ||||||||
|
Garās pozīcijas nodeva naktij
Long position overnight fee
Doties uz platformu | -0.025457% | ||||||||
|
Īsās pozīcijas nodeva naktij
Short position overnight fee
Doties uz platformu | 0.003235% | ||||||||
| Nakts laika nodeva | 21:00 (UTC) | ||||||||
| Min. tirgotais daudzums | 1 | ||||||||
| Valūta | USD | ||||||||
| Drošības rezerve | 20% | ||||||||
| Fondu birža | United States of America | ||||||||
| Tirdzniecības komisija | 0% |
*Information provided by Capital.com
Altimmune Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Galvenie Statistikas Dati
| Iepriekš. aizvērt* | 4.11 |
| Atvērt* | 4.07 |
| Izmaiņas par 1 gadu* | -17.28% |
| Dienas Diapazons* | 4.07 - 4.23 |
| 52 ned Diapazons | 3.82-23.49 |
| Vidējais apjoms (10 dienas) | 1.43M |
| Vidējais apjoms (3 mēneši) | 45.19M |
| Tirgus Kapitalizācija | 199.14M |
| Cenas/Peļņas Attiecība | -100.00K |
| Izvietotās Akcijas | 49.29M |
| Ieņēmumi | -79.00K |
| EPS | -1.76 |
| Dividende (Ienesīgums %) | N/A |
| Beta | -0.07 |
| Nākamās Peļņas Datums | Aug 9, 2023 |
"Visus datus nodrošina Refinitiv, izņemot datus, kas atzīmēti ar zvaigznīti, kas ir *dati, kurus nodrošina Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Aizvēršana | Change | Change (%) | Atvēršana | High | Low |
|---|---|---|---|---|---|---|
| Jun 1, 2023 | 4.11 | 0.15 | 3.79% | 3.96 | 4.21 | 3.90 |
| May 31, 2023 | 4.02 | 0.08 | 2.03% | 3.94 | 4.13 | 3.93 |
| May 30, 2023 | 3.97 | -0.07 | -1.73% | 4.04 | 4.14 | 3.96 |
| May 26, 2023 | 4.06 | -0.12 | -2.87% | 4.18 | 4.22 | 4.00 |
| May 25, 2023 | 4.21 | 0.05 | 1.20% | 4.16 | 4.29 | 4.14 |
| May 24, 2023 | 4.27 | -0.09 | -2.06% | 4.36 | 4.40 | 4.18 |
| May 23, 2023 | 4.39 | 0.03 | 0.69% | 4.36 | 4.77 | 4.32 |
| May 22, 2023 | 4.44 | -0.01 | -0.22% | 4.45 | 4.58 | 4.38 |
| May 19, 2023 | 4.43 | 0.05 | 1.14% | 4.38 | 4.60 | 4.38 |
| May 18, 2023 | 4.42 | -0.07 | -1.56% | 4.49 | 4.55 | 4.25 |
| May 17, 2023 | 4.57 | -0.02 | -0.44% | 4.59 | 4.68 | 4.50 |
| May 16, 2023 | 4.62 | -0.17 | -3.55% | 4.79 | 4.86 | 4.60 |
| May 15, 2023 | 4.80 | -0.28 | -5.51% | 5.08 | 5.30 | 4.76 |
| May 12, 2023 | 5.05 | -0.28 | -5.25% | 5.33 | 5.52 | 4.96 |
| May 11, 2023 | 5.31 | 0.37 | 7.49% | 4.94 | 5.41 | 4.84 |
| May 10, 2023 | 4.92 | 0.03 | 0.61% | 4.89 | 5.06 | 4.73 |
| May 9, 2023 | 4.90 | 0.08 | 1.66% | 4.82 | 5.02 | 4.73 |
| May 8, 2023 | 4.89 | 0.01 | 0.20% | 4.88 | 4.94 | 4.74 |
| May 5, 2023 | 4.89 | 0.02 | 0.41% | 4.87 | 5.09 | 4.85 |
| May 4, 2023 | 4.89 | 0.01 | 0.20% | 4.88 | 4.98 | 4.64 |
Altimmune, Inc. Events
| Laiks (UTC) (UTC) | Valsts | Notikums |
|---|---|---|
| Wednesday, August 9, 2023 | ||
| Laiks (UTC) (UTC) 12:30 | Valsts US
| Notikums Q2 2023 Altimmune Inc Earnings Release Q2 2023 Altimmune Inc Earnings ReleaseForecast -Previous - |
| Friday, September 29, 2023 | ||
| Laiks (UTC) (UTC) 12:30 | Valsts US
| Notikums Altimmune Inc Annual Shareholders Meeting Altimmune Inc Annual Shareholders MeetingForecast -Previous - |
| Wednesday, November 8, 2023 | ||
| Laiks (UTC) (UTC) 13:30 | Valsts US
| Notikums Q3 2023 Altimmune Inc Earnings Release Q3 2023 Altimmune Inc Earnings ReleaseForecast -Previous - |
- Ikgadējs
- Ceturkšņa
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Kopējie ienākumi | -0.068 | 4.41036 | 8.18503 | 5.8014 | 10.3312 |
| Ienākumi | -0.068 | 4.41036 | 8.18503 | 5.8014 | 10.3312 |
| Kopējie Darbības Izdevumi | 87.672 | 101.324 | 62.9838 | 27.2663 | 53.1656 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 17.134 | 15.4133 | 13.2094 | 8.50078 | 9.76558 |
| Pētniecība un Attīstība | 70.538 | 74.5212 | 49.7275 | 17.618 | 18.3757 |
| Neparedzēti Izdevumi (Ienākumi) | 0 | 11.37 | 0 | 1 | 24.9407 |
| Darbības Izdevumi | -87.74 | -96.914 | -54.7987 | -21.4649 | -42.8344 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | 2.862 | 0.19708 | 0.31309 | 0.87117 | -2.76442 |
| Citi, Neto | -0.032 | -0.37387 | 0.02415 | 0.01514 | 0.27789 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | -84.91 | -97.0908 | -54.4615 | -20.5786 | -45.3209 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | -84.713 | -97.0908 | -49.0445 | -20.5201 | -39.1712 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | -84.713 | -97.0908 | -49.0445 | -20.5201 | -39.1712 |
| Neto Ienākumi | -84.713 | -97.0908 | -49.0445 | -20.5201 | -39.1712 |
| Total Adjustments to Net Income | 0 | -0.45293 | -3.3078 | ||
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -84.713 | -97.0908 | -49.0445 | -20.9731 | -42.479 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -84.713 | -97.0908 | -49.0445 | -20.9731 | -42.479 |
| Atšķaidītie Neto Ienākumi | -84.713 | -97.0908 | -49.0445 | -20.9731 | -42.479 |
| Atšķaidītie Ienākumi par Akcijām | 46.9263 | 41.2835 | 25.637 | 13.125 | 2.80238 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -1.80523 | -2.35181 | -1.91303 | -1.59795 | -15.1582 |
| Dividends per Share - Common Stock Primary Issue | |||||
| Atšķaidītā Normalizētā Peļņa par Akciju | -1.80523 | -2.07639 | -1.91303 | -1.54843 | -9.37328 |
| Depreciation / Amortization | 0.01992 | 0.04681 | 0.1475 | 0.08365 | |
| Ārkārtas Posteņi Kopā | 0 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Kopējie ienākumi | 0.021 | -0.068 | 0.002 | 0.008 | 0.032 |
| Ienākumi | 0.021 | -0.068 | 0.002 | 0.008 | 0.032 |
| Kopējie Darbības Izdevumi | 21.78 | 87.672 | 24.754 | 20.403 | 19.531 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 4.531 | 17.134 | 4.492 | 4.41 | 4.427 |
| Pētniecība un Attīstība | 17.249 | 70.538 | 20.262 | 15.993 | 15.104 |
| Darbības Izdevumi | -21.759 | -87.74 | -24.752 | -20.395 | -19.499 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | 1.666 | 2.862 | 0.989 | 0.263 | -0.041 |
| Citi, Neto | 0.019 | -0.032 | 0.05 | 0.025 | 0.11 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | -20.074 | -84.91 | -23.713 | -20.107 | -19.43 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | -20.074 | -84.713 | -23.516 | -20.107 | -19.43 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | -20.074 | -84.713 | -23.516 | -20.107 | -19.43 |
| Neto Ienākumi | -20.074 | -84.713 | -23.516 | -20.107 | -19.43 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -20.074 | -84.713 | -23.516 | -20.107 | -19.43 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -20.074 | -84.713 | -23.516 | -20.107 | -19.43 |
| Atšķaidītie Neto Ienākumi | -20.074 | -84.713 | -23.516 | -20.107 | -19.43 |
| Atšķaidītie Ienākumi par Akcijām | 50.1257 | 46.9263 | 49.2865 | 47.5026 | 43.9695 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -0.40047 | -1.80523 | -0.47713 | -0.42328 | -0.4419 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Atšķaidītā Normalizētā Peļņa par Akciju | -0.40047 | -1.80523 | -0.47713 | -0.42328 | -0.4419 |
| Neparedzēti Izdevumi (Ienākumi) | 0 | 0 | 0 |
- Ikgadējs
- Ceturkšņa
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 192.813 | 204.126 | 230.257 | 39.3947 | 39.3721 |
| Nauda un Īstermiņa Ieguldījumi | 184.88 | 190.301 | 215.923 | 37.2401 | 33.7187 |
| Nauda un Ekvivalenti | 111.097 | 190.301 | 115.918 | 8.96269 | 33.7187 |
| Debitoru Parādu Kopsumma, Neto | 2.541 | 5.83848 | 12.373 | 1.65028 | 4.47091 |
| Accounts Receivable - Trade, Net | 0.173 | 0.42884 | 4.6102 | 1.02118 | 3.46194 |
| Prepaid Expenses | 5.358 | 7.95269 | 1.92668 | 0.47023 | 0.54809 |
| Other Current Assets, Total | 0.034 | 0.03417 | 0.03417 | 0.03417 | 0.63442 |
| Total Assets | 206.928 | 218.865 | 245.115 | 54.058 | 54.7505 |
| Property/Plant/Equipment, Total - Net | 1.677 | 2.24596 | 1.96075 | 1.80253 | 1.3428 |
| Property/Plant/Equipment, Total - Gross | 3.175 | 4.29284 | 3.55956 | 3.1501 | 2.45055 |
| Accumulated Depreciation, Total | -1.498 | -2.04688 | -1.59881 | -1.34757 | -1.10775 |
| Goodwill, Net | |||||
| Intangibles, Net | 12.419 | 12.419 | 12.8238 | 12.7322 | 13.8519 |
| Other Long Term Assets, Total | 0.019 | 0.0738 | 0.07341 | 0.12855 | 0.18368 |
| Total Current Liabilities | 17.054 | 18.2759 | 12.0204 | 3.923 | 4.52741 |
| Accounts Payable | 4.804 | 2.03449 | 0.61229 | 0.01823 | 0.37286 |
| Accrued Expenses | 11.081 | 10.1514 | 11.3884 | 3.8432 | 4.0632 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 1.169 | 6.09 | 0.01975 | 0.06156 | 0.01975 |
| Total Liabilities | 21.635 | 19.7301 | 19.2389 | 8.53787 | 6.43798 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0.50117 |
| Long Term Debt | 0 | 0.50117 | |||
| Deferred Income Tax | 0.0585 | ||||
| Other Liabilities, Total | 4.581 | 1.4542 | 7.21844 | 4.61488 | 1.3509 |
| Total Equity | 185.293 | 199.135 | 225.876 | 45.5201 | 48.3126 |
| Redeemable Preferred Stock | 0 | ||||
| Common Stock | 0.005 | 0.00409 | 0.0037 | 0.00151 | 0.00088 |
| Additional Paid-In Capital | 568.399 | 497.342 | 417.338 | 187.915 | 170.208 |
| Retained Earnings (Accumulated Deficit) | -377.884 | -293.171 | -186.421 | -137.376 | -116.856 |
| Other Equity, Total | -5.227 | -5.04016 | -5.04452 | -5.02016 | -5.04016 |
| Total Liabilities & Shareholders’ Equity | 206.928 | 218.865 | 245.115 | 54.058 | 54.7505 |
| Total Common Shares Outstanding | 49.1998 | 40.9938 | 37.1429 | 15.3122 | 9.07824 |
| Current Port. of LT Debt/Capital Leases | 0 | 0.0716 | |||
| Īstermiņa Ieguldījumi | 73.783 | 0 | 100.006 | 28.2774 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 173.111 | 192.813 | 211.004 | 195.504 | 191.093 |
| Nauda un Īstermiņa Ieguldījumi | 165.729 | 184.88 | 201.827 | 184.756 | 179.947 |
| Nauda un Ekvivalenti | 104.69 | 111.097 | 127.465 | 135.858 | 179.947 |
| Īstermiņa Ieguldījumi | 61.039 | 73.783 | 74.362 | 48.898 | |
| Debitoru Parādu Kopsumma, Neto | 3.37 | 2.541 | 4.353 | 6.095 | 6.073 |
| Accounts Receivable - Trade, Net | 0.252 | 0.173 | 0.633 | 0.195 | 0.193 |
| Prepaid Expenses | 3.978 | 5.358 | 4.79 | 4.619 | 5.039 |
| Other Current Assets, Total | 0.034 | 0.034 | 0.034 | 0.034 | 0.034 |
| Total Assets | 187.083 | 206.928 | 225.277 | 209.906 | 205.66 |
| Property/Plant/Equipment, Total - Net | 1.548 | 1.677 | 1.821 | 1.937 | 2.087 |
| Property/Plant/Equipment, Total - Gross | 3.175 | 3.212 | |||
| Accumulated Depreciation, Total | -1.498 | -1.125 | |||
| Intangibles, Net | 12.419 | 12.419 | 12.419 | 12.419 | 12.419 |
| Other Long Term Assets, Total | 0.005 | 0.019 | 0.033 | 0.046 | 0.061 |
| Total Current Liabilities | 14.951 | 17.054 | 15.742 | 13.845 | 19.124 |
| Accounts Payable | 5.238 | 4.804 | 1.419 | 2.872 | 2.205 |
| Accrued Expenses | 8.544 | 11.081 | 13.154 | 10.973 | 12.609 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 1.169 | 1.169 | 1.169 | 0 | 4.31 |
| Total Liabilities | 19.351 | 21.635 | 20.248 | 15.371 | 20.792 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 4.4 | 4.581 | 4.506 | 1.526 | 1.668 |
| Total Equity | 167.732 | 185.293 | 205.029 | 194.535 | 184.868 |
| Common Stock | 0.005 | 0.005 | 0.005 | 0.005 | 0.004 |
| Additional Paid-In Capital | 570.786 | 568.399 | 566.551 | 532.398 | 502.505 |
| Retained Earnings (Accumulated Deficit) | -397.958 | -377.884 | -356.224 | -332.708 | -312.601 |
| Other Equity, Total | -5.101 | -5.227 | -5.303 | -5.16 | -5.04 |
| Total Liabilities & Shareholders’ Equity | 187.083 | 206.928 | 225.277 | 209.906 | 205.66 |
| Total Common Shares Outstanding | 49.2867 | 49.1998 | 49.1616 | 46.3721 | 43.2199 |
- Ikgadējs
- Ceturkšņa
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Neto ienākumi/Sākuma Līnija | -84.713 | -97.0908 | -49.0445 | -20.5201 | -39.1712 |
| Nauda no Darbības | -62.586 | -78.2379 | -34.3058 | -9.602 | -9.38891 |
| Nauda no Darbības | 0.5513 | 0.42888 | 0.23982 | 0.21872 | |
| Amortization | 0.1475 | 0.08365 | |||
| Bezskaidras Naudas Preces | 8.016 | 18.5521 | 18.8219 | 8.76996 | 28.6495 |
| Cash Taxes Paid | 0 | 0.00179 | 0 | 0.05721 | |
| Izmaiņas Apgrozāmajā Kapitālā | 14.111 | -0.25053 | -4.51216 | 1.81936 | 6.98019 |
| Nauda no Ieguldījumu Darbībām | -73.399 | 87.5231 | -72.2258 | -28.2864 | -1.00114 |
| Kapitālie Izdevumi | -0.126 | -12.3117 | -0.34242 | -0.029 | -1.01563 |
| Citi Ieguldījumu Naudas Plūsmas Posteņi, Kopā | -73.273 | 99.8348 | -71.8834 | -28.2574 | 0.01449 |
| Nauda no Darbībām ar Finansēšanu | 56.781 | 65.0978 | 213.487 | 12.5321 | 32.4899 |
| Naudas Plūsma Finansēšanas Posteņos | 0 | -0.11852 | 0 | ||
| Akciju Izsniegšana (Atkāpšanās), Neto | 56.781 | 65.2163 | 213.487 | 12.8241 | 34.0396 |
| Parādu Izsniegšana (Atkāpšanās), Neto | 0 | 0 | -0.292 | -1.5497 | |
| Ārvalstu Valūtas Ietekme | -0.05037 | ||||
| Neto Izmaiņas Naudā | -79.204 | 74.383 | 106.955 | -25.3563 | 22.0495 |
| Deferred Taxes | -0.0585 | -6.14979 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -20.074 | -84.713 | -63.053 | -39.537 | -19.43 |
| Cash From Operating Activities | -19.407 | -62.586 | -45.28 | -30.23 | -13.526 |
| Cash From Operating Activities | 0.031 | 0.172 | 0.119 | ||
| Non-Cash Items | 2.301 | 8.016 | 6.112 | 4.033 | 0.143 |
| Changes in Working Capital | -1.634 | 14.111 | 11.63 | 5.102 | 5.642 |
| Cash From Investing Activities | 13.302 | -73.399 | -74.38 | -48.977 | -0.009 |
| Capital Expenditures | -0.051 | -0.126 | -0.088 | -0.028 | -0.009 |
| Other Investing Cash Flow Items, Total | 13.353 | -73.273 | -74.292 | -48.949 | 0 |
| Cash From Financing Activities | -0.302 | 56.781 | 56.824 | 24.764 | 3.181 |
| Financing Cash Flow Items | -0.013 | 0 | 0 | -0.036 | -0.119 |
| Issuance (Retirement) of Stock, Net | -0.289 | 56.781 | 56.824 | 24.8 | 3.3 |
| Net Change in Cash | -6.407 | -79.204 | -62.836 | -54.443 | -10.354 |
| Cash Taxes Paid | |||||
| Issuance (Retirement) of Debt, Net |
| Investora vārds | Investora veids | Nenokārtots procents | Akcijas turējumā | Izmaiņas akcijās | Turēšanas termiņš | Apgrozījuma reitings |
|---|---|---|---|---|---|---|
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 10.0609 | 4959254 | -955334 | 2023-03-31 | LOW |
| Laurion Capital Management LP | Hedge Fund | 7.1032 | 3501330 | 2750030 | 2023-03-31 | HIGH |
| Nuveen LLC | Pension Fund | 6.63 | 3268061 | 2098 | 2023-03-31 | LOW |
| Tang Capital Management, LLC | Hedge Fund | 5.579 | 2750000 | 49550 | 2023-03-31 | MED |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 5.1227 | 2525113 | 5301 | 2023-03-31 | LOW |
| Citadel Advisors LLC | Hedge Fund | 4.1477 | 2044485 | 885024 | 2023-03-31 | HIGH |
| Two Sigma Investments, LP | Hedge Fund | 4.1162 | 2028982 | 327385 | 2023-03-31 | HIGH |
| Marshall Wace LLP | Investment Advisor/Hedge Fund | 3.2401 | 1597130 | 357336 | 2023-03-31 | HIGH |
| Ardsley Advisory Partners LP | Hedge Fund | 2.9361 | 1447250 | 742500 | 2023-03-31 | MED |
| Avidity Partners Management LP | Hedge Fund | 2.6682 | 1315200 | -2674800 | 2023-03-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 2.6611 | 1311736 | 9245 | 2023-03-31 | LOW |
| Millennium Management LLC | Hedge Fund | 2.1682 | 1068745 | 924007 | 2023-03-31 | HIGH |
| Goldman Sachs & Company, Inc. | Research Firm | 1.6723 | 824323 | 86346 | 2023-03-31 | MED |
| Susquehanna International Group, LLP | Investment Advisor | 1.6163 | 796722 | 444649 | 2023-03-31 | MED |
| Qube Research & Technologies Ltd | Hedge Fund | 1.385 | 682680 | 670035 | 2023-03-31 | HIGH |
| Ikarian Capital LLC | Hedge Fund | 1.3741 | 677300 | 403868 | 2023-03-31 | HIGH |
| BofA Global Research (US) | Research Firm | 1.3108 | 646146 | 123630 | 2023-03-31 | LOW |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 1.1493 | 566501 | 388636 | 2023-03-31 | LOW |
| Tri Locum Partners LP | Hedge Fund | 1.0728 | 528814 | 203120 | 2023-03-31 | LOW |
| Rafferty Asset Management LLC | Investment Advisor/Hedge Fund | 1.048 | 516563 | -82324 | 2023-03-31 | MED |
Kāpēc izvēlēties Capital.com? Mūsu skaitļi runā paši par sevi.
Capital.com Group535K+
Tirgotāji
87K+
Ikmēneša aktīvie klienti
$113M+
Ikmēneša ieguldījumu apjoms
$64M+
Izņemts katru mēnesi
Treidinga kalkulators
Aprēķiniet iespējamo peļņu un zaudējumus, uzsākot CFD darījumu noteiktā dienā (izvēlaties datumu) un slēdzot darījumu citā dienā (izvēlaties datumu).
Tirdzniecības komisija
0
- 1:1
Finanšu svira
1:1
- 20
- 100
- 500
- 1000
- 10000
Investīcija
Darījuma apjoms (Kredītplecs x Investīcija):
Atvēršana
Aizvēršana
Īss Garšs
Altimmune, Inc. Company profile
Par Altimmune, Inc.
Altimmune, Inc. ir klīniskās stadijas biofarmācijas uzņēmums, kas nodarbojas ar aptaukošanās un aknu slimību ārstēšanas līdzekļu izstrādi. Uzņēmuma vadošais kandidātprodukts - pemvidutids (ierosinātais INN, agrāk pazīstams kā ALT-801) - ir GLP-1/glukāgona duālo receptoru agonists, kas tiek izstrādāts aptaukošanās un nealkoholiskā steatohepatīta (NASH) ārstēšanai. Uzņēmums izstrādā arī HepTcell - imunoterapeitisku līdzekli, kas paredzēts hroniska hepatīta B funkcionālai izārstēšanai. Uzņēmums ir uzsācis HepTcell II fāzes klīnisko izpēti un veic pemvidutida II fāzes un I fāzes klīnisko izpēti vairākām indikācijām. Uzņēmums veic HepTcell II fāzes klīnisko pētījumu Amerikas Savienotajās Valstīs, Apvienotajā Karalistē, Kanādā, Vācijā un Spānijā un veic pemvidutida I fāzes klīnisko pētījumu Austrālijā. Uzņēmumam pilnībā piederošie meitasuzņēmumi ir Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC un Altimmune AU Pty, Limited.
| Industry: | Bio Therapeutic Drugs |
910 Clopper Rd Ste 201S
GAITHERSBURG
MARYLAND 20878-1361
US
Peļņas Atskaite
- Annual
- Quarterly
Cilvēki arī skatās
Vai joprojām meklējat mākleri, kuram varat uzticēties?
Pievienojieties 535 000+ tirgotājiem visā pasaulē, kuri izvēlējās tirgoties ar Capital.com